Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT https://t.co/dShyBF4WST

RA-ILD: 💡Lifetime prevalence seems low but ~40% can have subclincal. 💡Screen early in symptomatic pts. 💡RA disease control decreases ILD progression and mortality. 💡RA-ILD UIP pattern seems to respond to immunosuppression. #ACR24 @RheumNow https://t.co/q3iACMeYVU

When you stop 🛑 #TCZ #tocilizumab at 6 months of #Rx in #PMR RELAPSES are V high DON’T stop #Toci in PMR too Early Rapid and frequent flares #ACR24 @RheumNow @ACRheum #1698 https://t.co/IX5EJOcIY5

A#1692 Single cell RNA-seq identifies double-negative-2 (DN2) B-cell population ass w progressive SSc-ILD IgD- CD27- cluster is highest risk CD21 low B cells are distinct subset associated with sclerosis, pHTN DN2 B cells as potential biomarkers for SSc-ILD @RheumNow #ACR24 https://t.co/IbnOGS8C3t

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx

Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR

A#1690 fibroblast activation protein inhibitor (FAPI)-PET in SSc ILD Introduces FAPI quantification algorithm FAPI uptake predicts greater rate of FVC decline. Trend for DLCO, not statistically signif FAPI volume & intensity both predict accel lung decline #ACR24 @RheumNow https://t.co/YA2ptLDaMy

Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj

Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL